Doubts Mount About Valeant Pharmaceuticals’ Tax Structures

MONTREAL – The disclosure by Valeant Pharmaceuticals International Inc. that it is under audit by the U.S. Internal Revenue Service is raising further doubts among tax specialists about the future of the Quebec-based drug company’s tax strategies. Valeant estimates it has achieved US$2.5-billion in tax and other “corporate structure” savings since merging with Ontario’s Biovail Corp.…

Valeant Pharmaceuticals under threat from tax audits, analysts say



About the Author

Financial Post
The Financial Post delivers all the news and analysis you need to operate in today's competitive business environment. The Post's team of reporters cut through the noise and deliver the facts you need to make the right decisions - fast. If you're looking for incisive business commentary, you'll find it here. The Financial Post boasts Canada's most respected business voices including Terence Corcoran, Diane Francis, Barry Critchley and Theresa Tedesco.